Business

Mass. Movers

EU panel supports OK of Aegerion drug

istockphoto.com

Shares of Cambridge’s Aegerion Pharmaceuticals Inc. rose after the company said that a European Union advisory panel recommended its drug be approved as a treatment for a rare inherited disease that causes high levels of bad cholesterol. Regulators are expected to make a decision in the third quarter. The pill, Lojuxta, is intended to be used along with a low-fat diet and other methods intended to reduce bad LDL cholesterol. US regulators approved the drug in December. Here, it is marketed under the name Juxtapid.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.